Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Definiens AG. (8/2/16). "Press Release: Definiens Launches Clinical Development Offering to Provide Services from Discovery to Commercialization to Maximize the Success of Drug Programs". Munich.

Organisations Organisation Definiens AG
  Group AstraZeneca (Group)
  Organisation 2 Affect Inc.
Products Product Definiens Clinical Development Offering (Clinical Trial Services, Signature Disocvery Services, Companion Dx Services)
  Product 2 Tissue Phenomics™
Persons Person Heydler, Thomas P. (Definiens 200411– CEO)
  Person 2 Baratta, Melissa (Affect PR 201505)

New Service Provides Comprehensive Solution for Tissue-Based Assay Development, Image Analysis and Biomarker Signature Discovery

Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, today announced the release of its Clinical Development Offering, making the company the premier provider of comprehensive tissue-based services from discovery to commercialization. The new service enables pharmaceutical companies to improve patient outcomes and reduce pipeline risk, ultimately moving therapies to market more quickly and improving the success of drug programs.

Leveraging Tissue Phenomics, Definiens provides robust and precise quantitative IHC, ISH, and IF assays to identify tissue features in context that can be easily combined with other data types to mine for clinically relevant patterns.

The focus of our new Definiens clinical development offering is to support our partners in maximizing their pipeline, to accurately identify patient populations and therefore deliver the right therapy, said Thomas Heydler, CEO, Definiens. We are now providing image analysis, data mining and assay development, combined with deep scientific, regulatory and pathology support. Its truly an end-to-end offering for biopharma, he adds.

The Clinical Development Offering provides a number of services:

Clinical Trial Services

> Drive Pipeline Decisions: Gain biological insights from custom tissue-based assays & quantitative image analysis solutions to drive pipeline decisions in your clinical trials.

Signature Discovery Services

> Discover the Best Signatures: Utilize our unparalleled data mining on your tissue samples to find novel signatures and assess the potential of a biomarker to identify patient populations.

Companion Diagnostics Services

> Deliver Precise CDx to the Market: With precise quantitative biomarker readouts, best-in-class, co-developed assays ensure fast movement from prototype to regulatory filing.

To learn more about Definiens Clinical Development Offering, please contact us. For more information about Definiens, visit

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit:

Media Contacts

Melissa Baratta
+1 212-398-9680

Record changed: 2016-09-15


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top